No registrations found.
ID
Source
Health condition
RA, HR-pQCT, MRI, US, RX, bone erosions
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary outcome of the study is 1/ cross-sectionally - the prevalence of bone erosions and 2/ longitudinally - the progression of bone erosions in the 2nd and 3rd proximal interphalangeal (PIP) joints and metacarpophalangeal (MCP) joints of the hands bilaterally in patients with RA. In healthy controls only the dominant hand will be scanned and includes also the 2nd and 3rd distal interphalangeal (DIP) joints ,using the HRpQCT (800 RA joints + 480 healthy control joints in the total study).
Secondary outcome
Secondary outcomes are the comparison of the number of joints with erosions detected by HRpQCT with 1/ the number of joints with erosions detected by X-rays, MRI and US and 2/ the number of joints with osteitis by MRI; exploring possibilities to quantify the 3-D joint space volume occupied by cartilage; and the correlation between the prevalence and progression of erosions with serum bone turnover markers.
Background summary
Evaluation of the prevalence, incidence and progression of bone erosions in rheumatoid arthritis (RA) by high-resolution peripheral quantitative computer tomography (HRpQCT) compared to standard imaging techniques
Study objective
Imaging by HR-pQCT is more precise and more sensitive than CR and MRI for demonstrating differences (from controls) and changes in 3D microarchitecture of cortical bone (number, size and location of erosions, osteophytes), trabecular bone (destruction, sclerosis, healing) and indirectly of 3D cartilage volume in-vivo of hand joints in patients with hand RA and healthy controls, both cross-sectionally and longitudinally.
Study design
First year inclusion and measurements, followed by follow-up.
Intervention
25 early and 25 late female reumatoïd arthritis patients, and 40 age matched female healthy controls will be included and studied by MRI, RX, US and HR-pQCT imaging of finger joints (MCP, PIP, DIP).
Inclusion criteria
4.2 Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Healthy controls:
1. Not known with any form of rheumatic disease
2. Subjects who understand the conditions of the study and are willing and able to comply with the scheduled evaluations.
3. Subjects who signed the Ethics Committee approved specific Informed Consent Form prior to inclusion.
Patients with RA:
1. Patients who are diagnosed with RA, based on the universally accepted ACR/EULAR criteria.
2. Patients who understand the conditions of the study and are willing and able to comply with the scheduled evaluations.
3. Patients who signed the Ethics Committee approved specific Informed Consent Form prior to inclusion.
Exclusion criteria
A subject who meets any of the following criteria will be excluded from participation in this study:
1. Patients who underwent surgery of the hand or fingers or who are expected to need surgery of the hand in due course
2. Patients with malignancy in the last 12 months
3. Patients with a neuromuscular or neurosensory deficit which would limit the ability to assess the affected joint during the HR-pQCT evaluation.
4. Patients with known systemic or metabolic disorders leading to progressive bone deterioration such as:
a. Primary hyperthyroidism
b. Primary hyperparathyroidism
c. Chronic kidney disease with eGFR< 30 ml/min.
d. Sarcoidosis
5. Patients who, as judged by the principal investigator, are mentally incompetent or unlikely to be compliant with the follow-up evaluation schedule.
6. Patients with other rheumatic disorders involving the joints, such as osteoarthritis
7. Patients who are pregnant or willing to become pregnant or are breastfeeding.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4392 |
| NTR-old | NTR4523 |
| CCMO | NL42300.068.12 |
| OMON | NL-OMON41257 |